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OutcomeThe impact of donor body mass index (BMI) on graft function outcomes in liver transplantation (LT) is still
controversial. The aim of this study was to review the current evidence investigating the effect of donor BMI
on outcomes in patients undergoing LT. A systematic review was performed to evaluate relevant outcomes
such as the availability of data on donor BMI aswell as graft and patient survival after LT. Screening of 901 articles
resulted in 11 observational studies for data extraction. In adult deceased donor after brain death and living
donor LT, donor BMIwas not associatedwith graft and patient survival. However, high donor BMIwas associated
with a higher chance of macrosteatosis besides a significantly higher incidence of declined livers. In pediatric LT,
severe obesity in adult donors with BMI ≥35 was associated with graft loss and mortality, whereas obesity in
pediatric donors was not associated with graft loss and mortality. Accordingly, donor BMI is not associated
with long-term outcomes in adult patients undergoing LT. However, further research should be conducted to
identify the effect of donor BMI on outcomes in LT.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://
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In the past three decades obesity has become a pandemic; global
obesity prevalence is foreseen to reach 21% in women and 18% in men
by 2025 [1,2]. A recent study has shown that the prevalence of age-
standardized obesity increased from 6.4% in 1975 to 14.9% in 2014 in
women and from 3.2% to 10.8% in men [3]. The increasing prevalence
of overweight and obesity will inherently lead to an increasing number
of obese organ donors.
Strict donor pool selection criteria, especially from extended criteria
donors (ECDs) such as high body mass index (BMI) donors, are crucial
to obtain good clinical outcomes after liver transplantation (LT). The
common index to predict post-transplant outcomes in LT is the Donor
Risk Index (DRI). However, DRI does not include donor BMI as a risk fac-
tor [4,5]. In contrast, several ECDs include donor BMI as risk factor
where acceptable outcomes from extended criteria donors have been
reported [6–8].
The impact of donor BMI on graft function in LTwas first reported in
2003 based on the United Network for Organ Sharing (UNOS) database,
showing no influence for outcomes in LT [9]. Several studies on donor
BMI in LT have been conducted after that, with conflicting results re-
ported [10–12]. Moreover, the effect of donor BMI differs per field in
LT, including deceased donor LT (DDLT), living donor LT (LDLT), and
pediatric LT.
To date, the effect of donor BMI on graft function outcomes in LT
has not yet been systematically reviewed. Therefore, the aim of this
systematic review was to investigate the association of donor BMI
with post-transplant outcomes in patients undergoing DDLT, LDLT,
and pediatric LT, focusing on comparing outcomes between lower and
higher donor BMI.2. Material and methods
2.1. Literature search strategy
A systematic literature search of Embase, Medline Ovid, Web of Sci-
ence, and Cochrane CENTRAL was performed on the 1st of February
2020 using the following key words: liver transplantation, donor, and
body mass index. The full search terms are available in Supplementary
Table 1. The search was limited to the English language without limita-
tions of the publication year. This study is reported according to the Pre-
ferred Reporting Items for Systematic Reviewers and Meta-Analyses
(PRISMA) guidelines [13].2.2. Inclusion and exclusion criteria
The present study included articles investigating the association of
donor BMIwith outcomes in patients undergoing DDLT, LDLT, and pedi-
atric LT, focusing on comparing outcomes between lower and higher
donor BMI. Review articles, records without abstract, articles without
sufficient data, conference abstracts, and case reports were excluded.Fig. 1. PRISMA 2009 Flow Diagram.2.3. Data extraction
First duplicate records were removed. Subsequently abstracts were
screened to determine eligible studies for further analysis, and full-
text articles of the remaining recordswere subsequently reviewed inde-
pendently by two investigators (KT and RdW). The extracted data were
as follows: study information (year, study design, study period, and
number of patients included), donor and recipient information (type
of donor, donor BMI, and recipient characteristics), post-transplant out-
comes (donor and recipient complications including primary non-
function [PNF] and retransplantation, and long-term outcomes such as
graft and patient survival), and follow-up period.22.4. Assessment of study quality
The methodological quality of the included studies was evaluated
using the Newcastle-Ottawa quality assessment scale for cohort studies
[14]. Studieswith a total scorewith 6 or higherwere considered ashigh-
quality [15].
3. Results
A systematic literature search identified 901 articles (Fig. 1). After
excluding duplicate articles and screening the abstracts, 15 full-text ar-
ticles were reviewed. Finally, 11 articles [9–12,16–22] were included in
the present study since necessary data were not available from 4
articles.
The characteristics of the included studies are summarized in
Table 1. Out of 11 studies, ten were retrospective series and one was
prospective study using the UNOS database. Different cut-off values of
BMI were used in each study.
The assessment of methodological quality of the included studies
was demonstrated in Table 2. Out of 11 studies, 10 were evaluated as
high-quality with a total score of 6 or higher.
3.1. Impact of donor BMI on graft function in adult deceased donor liver
transplantation
Three studies from theUNOSdatabase have been published to inves-
tigate the effect of donor BMI in adult DDLT. Yoo et al. analyzed 22,303
LT recipients in the period 1987–2001 for which four groups were de-
fined based on donor BMI: BMI <25 (n = 11,660), 25 to 29.9 (n =
7418), 30 to 34.9 (n = 2301), and ≥35 (n = 924) [9]. They observed
that the incidence of PNF and early retransplantation rates were similar
among the groups, and concluded that donor BMI or moderate steatosis
did not influence short-term and long-term outcome of LT. A second
prospective observational study by Bloom et al. was conducted from
2008 to 2011 in the UNOS Region 5 [12]. During this period, 730 livers
were transplanted from 961 donors (76%) where donor BMI was iden-
tified as one of independent predictors of liver use (odds ratio [OR]
0.94, P = 0.001). Multivariable analysis found that lower donor BMI
(OR 0.91, P = 0.009) was associated with improved graft survival. A
third study by Steggerda et al. evaluated trends in the utilization and
outcomes based on donor BMI and the potential role of liver biopsy in
Table 1
Literatures reporting the effect of donor body mass index on outcomes in liver transplantation.
Study Year Study design Study period Number Type of donor Recipients Cut-off of donor BMI Reported outcome Follow-up
Yoo et al. [9] 2003 UNOS
Retrospective
1988–2001 22,303 Deceased (DBD) Adults <25 (n= 11,660)
25–30 (n= 7418)
30–35 (n= 2301)
>35 (n= 924)
PNF
Retransplantation
Graft survival
Patient survival
n.a.
Garcia et al. [10] 2004 Single center
Retrospective
1982–1999 301 Deceased (DBD) Adults
PBC
<25 (n= 203)
25–29.9 (n= 90)
30–39.9 (n= 7)
>40 (n= 1)
PNF
Graft survival
Patient survival
56 months (mean)
Moss et al. [16] 2005 Single center
Retrospective
1998–2003 68 Living Adults <30 (n= 52)
>30 (n= 16)
Donor complications
Recipient complications
Patient survival
25 months (median)
Wigg et al. [11] 2005 Single center
Retrospective
1992–2004 110 Deceased (DBD) Adults
ALF
n.a. Early mortality
Patient survival
n.a.
Perito et al. [17] 2012 UNOS
Retrospective
1990–2010 3788 Living
Deceased (DBD)
Pediatric <25
25–35
>35
Mortality
Graft survival
Patient survival
n.a.
Bloom et al. [12] 2015 UNOS
Prospective
2008–2011 730 Deceased (DBD) Adults <25 (n= 167)
25–30 (n= 125)
30–35 (n= 61)
>35 (n= 25)
Graft survival 74 ± 73 days
Andert et al. [18] 2016 Single center
Retrospective
2010–2014 163 Deceased (DBD) Adults <30 (n= 111)
30–39 (n= 31)
>40 (n= 15)
PNF
Retransplantation
Mortality
Graft survival
Patient survival
n.a.
Knaak et al. [19] 2017 Single center
Retrospective
2000–2014 469 Living Adults <30 (n= 364)
30–35 (n= 105)
Donor complications
Recipient complications
Retransplantation
Mortality
Graft survival
Patient survival
n.a.
Pischke et al. [20] 2017 Single center
Retrospective
1997–1999 114 Deceased (DBD) Adults <24
>24
Graft survival
Patient survival
171 months (median)
Molina et al. [21] 2019 Single center
Retrospective
2006–2014 225 Deceased (DBD) Adults <30 (175)
>30 (50)
Complications
Retransplantation
Graft survival
Patient survival
n.a.
Steggerda et al. [22] 2019 UNOS
Retrospective
2006–2016 60,200 Deceased (DBD) Adults <30
>30
Graft survival n.a
UNOS, UnitedNetwork for Organ Sharing; DBD, donors after brain death; PNF, primary non-func primary non-function tion; PBC, primary biliary cirrhosis; ALF, acute liver failure; n.a., not
available.
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(n = 60,200) [22]. Utilization rates from higher donor BMI (≥30) and
lower BMI (<30) were 73.7% and 84.3% (P < 0.001), respectively.
Pretransplant biopsy was performed more frequently in high BMI do-
nors (52.1% versus 33.1%, P < 0.001) and macrosteatosis (≥30%) was
identified more often compared to lower BMI donors (21.1% versus
12.2%, P < 0.001). Nonetheless, graft survival showed no significantTable 2
The Newcastle-Ottawa scale for quality assessment of include studies [14].
Study Selection
Representativeness
of the exposed
cohort
Selection of
the
non-exposed
cohort
Ascertainment
of exposure
Demonstrati
outcome of i
not present
study
Total score 1 1 1 1
Yoo et al. [9] 1 1 1 0
Garcia et al. [10] 1 1 1 0
Moss et al. [16] 1 1 1 0
Wigg et al. [11] 1 1 1 0
Perito et al. [17] 1 1 1 0
Bloom et al. [12] 1 1 1 0
Andert et al. [18] 1 1 1 0
Knaak et al. [19] 1 1 1 0
Pischke et al. [20] 1 1 1 0
Molina et al. [21] 1 1 1 0
Steggerda et al. [22] 1 1 1 0
3difference between recipients with lower donor BMI and higher donor
BMI (P = 0.44). However, grafts from higher donor BMI were
transplanted much less frequently.
Several single center retrospective studies have been reported re-
garding the effect of donor BMI in LT. Andert et al. evaluated the out-
come of 163 patients undergoing LT at the University Hospital Aachen
according to donor BMI categorized as <30, 30–39, and ≥ 40 [18].Comparability Outcome Total
score
on that
nterest was
at start of
Comparability of
cohorts on the
basis of the design
or analysis
Assessment
of outcome
Was follow-up
long enough
for outcomes
to occur
Adequacy
of follow
up of
cohorts
2 1 1 1 9
0 1 0 1 5
0 1 1 1 6
1 1 1 1 7
1 1 1 1 7
1 1 1 1 7
1 1 0 1 6
1 1 0 1 6
1 1 1 1 7
1 1 1 1 7
1 1 1 1 7
1 1 1 1 7
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dysfunction compared to BMI <30 and BMI ≥40 group (64.5%, 33.3% vs
26.7%, P = 0.005), the incidence of PNF (P = 0.72) and re-
transplantation (P= 0.07) was not significantly different between the
groups. In addition, patient and graft survival did not differ significantly
between the groups (patient survival, P=0.4). In a different study, Mo-
lina et al. compared outcomes between grafts from BMI ≥30 (n = 50)
and BMI <30 donors (n= 175) [21]. The Kaplan-Meier survival curve
showed no significant differences between the groups in terms of pa-
tient survival (P=0.50) and graft survival (P=0.44). In addition, mul-
tivariable analysis found that donor BMI was not associated with post-
transplant mortality. Pischke et al. revealed that recipient BMI was a
predictor of long-term survival after LT, whereas donor BMI was not as-
sociated with decreased survival [20].
Concerning the effect of donor BMI on disease-specific outcomes,
Garcia et al. conducted a retrospective analysis of 301 patients with pri-
mary biliary cirrhosis (PBC) following LT [10]. They observed that high
donor BMI ≥30 was not associated with overall graft and patient sur-
vival. In a study by Wigg et al. 110 patients with seronegative acute
liver failure transplanted between 1992 and 2004 were evaluated [11].
The multivariable analysis identified that donor BMI was the most pre-
dictive parameter associated with early death (OR 1.2, P= 0.009).
In summary, donor BMI was not associated with graft and patient
survival in adult DDLT. However high donor BMI was associated with
a higher incidence of macrosteatosis and the graft declination rate was
significantly higher. Notably, these results are based on donors after
brain death (DBD) and the effect of BMI in donors after circulatory
death (DCD) remains unknown.3.2. Impact of donor BMI on graft function in living donor liver
transplantation
Two studies have reported the impact of donor BMI on outcome in
LDLT [16,19]. First, Moss et al. evaluated 68 adult-to-adult LDLTs be-
tween 1998 and 2003 comparing 52 donors with BMI <30 and 16 do-
nors with BMI >30 [16]. With regard to recipient outcome, there was
no significant difference between grafts from donors with BMI >30
and < 30. Recipient survival was 80% with non-obese donors and
100% with obese donors with a median follow-up of 25 months (P =
0.1). The authors concluded that donors with BMI >30 may undergo
donor hepatectomy with acceptable recipient outcomes, and have the
potential to safely increase the donor pool.
In a different study by Knaak et al., the outcome of 469 adult LDLTs
encompassing donors with BMI <30 (n = 364) and donors with BMI
≥30 (n = 105) was reported [19]. In this study, donors with evidence
of >10% liver steatosis in the liver biopsy, regardless of their BMI,
were excluded from being donor candidates. Regarding recipient
short-term outcomes, overall complications during the first 30 days
after LDLT were significantly higher in the non-obese group (44% vs.
30%, P = 0.013), whereas major complications (Clavien-Dindo ≥3b)
were similar (25% vs. 20%, P=0.30). The incidence of 30-day mortality
was not different between the two groups (2% vs. 3%, P= 0.72). Long-
term recipient outcome following LDLT showed no significant differ-
ences between the BMI <30 and BMI ≥30 with respect to the incidence
of biliary complication (25% vs. 20%, P = 0.30), graft rejection (16% vs.
10%, P= 0.16), and retransplantation (5% vs. 5%, P= 1). Furthermore,
graft survival from donors with BMI <30 and ≥30 was similar at
1 year (91% vs. 87%), 5 years (81% vs. 75%) and 10 years (70% vs. 61%)
(P = 0.12). Likewise, no difference in patient survival was found be-
tween the groups at 1-year (93% vs. 90%), 5 years (83% vs. 78%) and
10-year follow-up (76% vs. 67%) (P = 0.12). The authors concluded
that donor BMI ≥30 in the absence of graft steatosis is no contraindica-
tion for LDLT.
In summary, donor BMI was not associated with graft and patient
survival in LDLT. Donor BMI should not be considered a4contraindication for living liver donation when the presence of
steatosis is within limits.
3.3. Impact of donor BMI on graft function in pediatric liver transplantation
The UNOS data for pediatric LT in the United States was reported in
2012 [17]. Between 2004 and 2010, 3788 pediatric LTs were performed
in the United States of which 1259 had adult donors, and 2529 had pe-
diatric donors. Thirty percent of the adult donorswere overweight (BMI
25–30), 8% were obese (BMI 30–35), and 2% were severely obese (BMI
≥35). Among pediatric donors, 16% were overweight, 6% were obese,
and 3% were severely obese. For pediatric recipients receiving adult
donor livers multivariate analysis showed (grafts from a living donor,
30%; deceased whole graft, 50%; deceased split graft, 20%), a donor
BMI of 25 to<35was not associatedwith graft survival (overweight do-
nors, hazard ratio [HR] 1.00, 95% confidence interval [CI] 0.73–1.36, P=
0.98; obese donors, HR 0.84, 95% CI 0.49–1.42, P = 0.50) and patient
survival (overweight donors, HR 1.20, 95% CI 0.81–1.78, P = 0.36;
obese donors, HR 0.95, 95% CI 0.48–1.89, P= 0.89). However, severely
obese donors were associated with increased risk of graft loss (HR
2.54, 95% CI 1.29–5.01, P = 0.007) and death (HR 3.56, 95% CI
1.64–7.72, P=0.001). Donor BMI of pediatric donorswasnot associated
with graft loss ormortality in uni- ormultivariate analysis. Furthermore,
an overweight or obese adult or pediatric donor was not a risk factor for
post-transplant obesity in recipients.
In summary, the evidence on the effect of donor BMI on graft func-
tion outcomes in pediatric LT is limited. Though, severe obesity in
adult donors (BMI ≥35) was associated with graft loss and mortality.
4. Discussion
There seems to be a growing trend of utilizing overweight and obese
donors for LT due to the increasing prevalence of overweight people
[23]. BMI is commonly used as a simple and objective index which cat-
egorizes overweight and obese [1,2], therefore we performed the preset
systematic review to gain a better understanding on the relationship be-
tween donor BMI and graft function after LT. After a systematic litera-
ture review, eleven observational studies were included. To the best
our knowledge, the present systematic review is the first to evaluate
the current evidence regarding the effect of donor BMI on outcomes in
LT, including DDLT, LDLT, and pediatric LT.
Although the increasing demand of organs in patients on waiting
lists and the shortage of organs have forced to utilize ECDs for graft
selection in LT, the assessment of liver grafts is still a difficult task
[24]. A previous study demonstrated that liver grafts with
macrosteatosis ≥30% was a risk factor of early graft dysfunction
and PNF, and utilization rates of grafts with macrosteatosis ≥30%
were low [22]. It is a well-known fact that the degree of histologi-
cally determined liver steatosis is a more reliable biomarker to pre-
dict graft suitability compared to donor BMI, however a problem is
that histological evaluation is not always available in clinical prac-
tice due to time limitations [18]. In addition, the quantification of
macrosteatosis using biopsy is strongly dependent on individual
pathologists and not reproducible [25]. Therefore it should make
sense to take donor BMI into account as a surrogate for hepatic
macrosteatosis as it is always available in clinical setting.
Based on our results, donor BMI was not associated with graft and
patient survival in adult DBD DDLT. However, high donor BMIwas asso-
ciated with a higher chance of macrosteatosis besides a significantly
higher incidence of declined livers. In LDLT, donor BMI was not associ-
atedwith graft and patient survival provided that pretransplant liver bi-
opsy did not reveal>10% steatosis. BMI itself should not be considered a
contraindication for donorship in LDLT, necessitating strict selection in-
cluding the absence of steatosis and donor comorbidities should be re-
quired. In pediatric LT, grafts from severely obese adult donors were
associated with increased risk of graft loss and mortality whereas for
K. Takagi, R.F. de Wilde, W.G. Polak et al. Transplantation Reviews 34 (2020) 100571obese pediatric donors there was no association. Accordingly, the evi-
dence of donor BMI on outcomes in LDLT and pediatric LT is limited
and the effect of BMI in DCD donors remains unknown.
Recent topic is how to improve the quality of organ from ECD in-
cluding older donor age, higher BMI, steatosis, and DCD by using ma-
chine perfusion as well as regional perfusion techniques [26–28].
Machine perfusion has been recognized as an evolving technology
that may not only enhance the performance of extended criteria
donor but might lead to optimized donor pool utilization [27]. There-
fore, recent developments in normothermic machine perfusion
might be beneficial (i.e. reversal of steatosis) to so-called ‘high-risk’
obese donor livers [29,30].
There are several limitations in the present study. Most of included
studies were retrospective data, therefore there might exist publication
bias. Regarding studies from the UNOS database, there exists a certain
overlapping between the studies by Bloom et al. [12] and by Steggerda
et al. [22], which might cause an elevated risk of overlapping for these
data. In addition, different cut-off values for BMI were used in each
study. Lastly, BMI could reflect a wide range of physical and clinical con-
ditions including obesity, malnutrition, and comorbidities. Therefore
BMImight be an anthropometric parameterwith heterogeneous clinical
applicability. However we believe that BMI is a useful parameter which
is always available in clinical practice.
5. Conclusions
The present systematic review represents the clinical significance of
donor BMI on graft function outcome in LT. In adult DDLT, donor BMI
was not associated with graft and patient survival. In LDLT, donor BMI
itself should not be considered a contraindication for donorship after
strict donor selection. In pediatric LT, grafts from severely obese adult
donors were associated with increased risk of graft loss and mortality,
while no association was found from obese pediatric donors. The evi-
dence of donor BMI on outcomes in LDLT and pediatric LT is still limited,
therefore further research iswarranted to clarify the clinical significance
of donor BMI on outcomes in the field of LT and explore the possibilities
of organ recovery in high risk livers.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.trre.2020.100571.
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